



February 17, 2026
StemRIM Inc.

StemRIM Announces Patent Registration (Canada) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders

Osaka, Japan, February 17, 2026 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; "StemRIM") announces that a patent will soon be registered in Canada for the application related to the novel treatment of cartilage disorders (including traumatic cartilage defect, osteoarthritis, osteochondritis dissecans, meniscal damage, and traumatic, inflammatory, or infectious arthritis) utilizing the peptide drug developed from the "Regeneration-Inducing Medicine™" development candidate Redasemtide (HMGB1 fragment peptide).

Title of Invention : Therapeutic agent for cartilage disorder
Region : Canada
Application No. : 3117107
Registration No. : To be determined
Applicant : StemRIM, Osaka University

This patent is intended to expand the indications for Redasemtide, which is currently under development, and we believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (including traumatic cartilage defect, osteoarthritis, osteochondritis dissecans, meniscal damage, and traumatic, inflammatory, or infectious arthritis) in Canada.

Cartilage disorders cause pain and functional impairment of the joint due to damage or degeneration of cartilage. Because cartilage has limited self-repair capacity, such disorders tend to become chronic and progressive.

It has been confirmed that intravenous administration of Redasemtide mobilizes bone marrow-derived mesenchymal stem cells (MSCs) into the bloodstream and promotes their accumulation at sites of tissue injury. Through this mechanism, Redasemtide is considered to facilitate tissue repair and regeneration in areas of cartilage damage within the knee joint. With its intravenous route of administration, which imposes a relatively low burden on patients, Redasemtide is anticipated to serve as a highly useful therapeutic option in clinical practice.

The impact on the financial performance for the fiscal year ending July 31, 2026, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with ectomesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

X: [@StemRIM_Inc](#)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)